Skip to main content
Lineage Cell Therapeutics Inc. logo

Lineage Cell Therapeutics Inc. — Investor Relations & Filings

Ticker · LCTX ISIN · US53566P1093 LEI · 5299002BI4W22SDF8R25 TA Manufacturing
Open in API
Filings indexed 2,777 across all filing types
Latest filing 2025-03-12 Director's Dealing
Country US United States of America
Listing TA LCTX

About Lineage Cell Therapeutics Inc.

https://lineagecell.com/

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel allogeneic cell therapies for unmet medical needs. The company's proprietary platform uses directed differentiation of pluripotent stem cells to manufacture specialized human cells. These "off-the-shelf" cell transplants are designed to replace or support dysfunctional cells in patients with serious conditions, aiming to restore or enhance physiological function. The therapeutic pipeline is focused on degenerative diseases of the eye, such as dry age-related macular degeneration, and neurological conditions, including spinal cord injury. The company leverages its integrated capabilities in cell line development, manufacturing, and delivery to advance its programs.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-03-12 English
4
Director's Dealing
2025-03-12 English
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Earnings Release Classification · 100% confidence The document is titled "Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" and contains detailed financial figures for both the fourth quarter and the full year ended December 31, 2024, including revenues, operating expenses (R&D and G&A), loss from operations, and net loss per share. This structure is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results, often accompanied by a business update and details about an upcoming conference call. While it contains comprehensive financial data, it is presented as a press release announcing the results, not the full, audited 10-K or a comprehensive Interim Report (IR) which typically follows a more standardized regulatory filing format. Since it explicitly announces the financial results for the period, 'ER' is the most appropriate classification over 'IR' (which is usually for comprehensive interim reports) or 'MDA' (which is management's detailed explanation following the release). Q4 2024
2025-03-11 English
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Report Publication Announcement Classification · 98% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. It contains a headline referencing 'Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update'. Crucially, the text states: 'Attached hereto is a report on *Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update* *Full_Year_2024_Financial_Results_isa.pdf*'. Since the document itself is an announcement stating that the full financial report is attached (and the document length is relatively short at 2056 characters), this fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive report itself (which would likely be classified as 10-K or IR if it were the full content).
2025-03-11 English
The company's financial results for the Fourth quarter and full year 2024 were reported abroad
Regulatory Filings Classification · 95% confidence The document is very short (370 characters) and states that the company's financial results for the fourth quarter and full year 2024 were reported abroad. It does not contain any actual financial data or detailed analysis, nor does it include the report itself. This matches the pattern of a brief announcement about a report rather than the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as a general announcement without substantive financial content.
2025-03-11 Hebrew (modern)
10-K
Annual Report FY 2024
2025-03-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.